|
Learn the basics of clinical trials in hepatitis C and find out about clinical trials that you may be eligible for.
 This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.
 How to Evaluate a Clinical Trial July 09
Making Sense of Hepatitis C Research and Medical Literature
 Guide to Understanding Clinical Trials and Medical Research in Hepatitis C
ClinicalTrials.gov
Provides regularly updated information about federally and
privately supported clinical research in human volunteers.
Centerwatch
Centerwatch list of hepatitis C clinical trials by state
We are recruiting patients for the following clinical tirals at Rush Univerity Hepatology:
1. Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
A study to develop observational clinical experience with the use of entecavir in patients who are either of Black/African-American race or of Hispanic ethnicity.
2. Study of TYZEKA in subjects of Black/African American or Hispanic/Latino origin with compensated chronic hepatitis B virus infection.
3. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy
4. Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin)
Contact:
Doris Yadav RN, BS
Senior Research Coordinator
Office: 312-563-3919
Fax: (312) 563-3920
Rush University Medical Center
1725 West Harrison Street
Suite 158 Professional Building
Chicago, Illinois 60612
HEAT Study: Hepatocellular Carcinoma of RFA and ThermoDox® Now Enrolling Recently Diagnosed HCC Patients in Clinical Trials
Celsion Corporation is an oncology drug development company which develops targeted chemotherapeutic treatments based on a unique heat-activated liposomal technology. Celsion is currently enrolling patients in a global Phase III clinical trial – the HEAT Study – which is designed to demonstrate the safety and efficacy of ThermoDox® in hepatocellular carcinoma (HCC) patients.
The HEAT study involves an investigational anti-cancer drug, called ThermoDox®, used in combination with an approved medical device for radiofrequency ablation (RFA) in the liver.
The study will be the largest investigation of RFA in HCC and will involve approximately 600 patients in over 40 research institutions in seven countries and regions.
ThermoDox is designed as a heat-activated liposomal technology that is administered intravenously. When used in combination with RFA to ablate tumors high concentrations of doxorubicin is released directly to the tumor and the surrounding liver tissue. The primary endpoint of the trial is progression-free survival. Details regarding the HEAT Study can be found here.
For more information, contact:
Jeannette Tighe, Principal
MedAdvisoryllc
7 Glenn Road, N. Easton, MA 02356
jtighe@medadvisory.net
508.297.2439
Clinical trial to test HuMax-HepC in people with a chronic hepatitis C infection
The purpose of the study is to determine the safety and tolerability of HuMax-HepC, to be given alone, in people with a chronic hepatitis C infection who have not had a sufficient response to other approved treatments of hepatitis C. Study drug and study procedures will be made available to you at no cost.
Contact:
Marjorie Small,
Research Coordinator
Biomedical Research Alliance of New York Mount Sinai Medical Center
Division of Liver Diseases
One Gustave L. Levy Place Box 1104
New York, NY 10029
Telephone: 212-241-1424
Email: Marjorie.small@mountsinai.org
A Study of Bavituximab (Chimeric Anti-Phosphtidylserine Monoclonal Antibody) in Co-Infected HCV and HIV patients
This study is currently recruiting patients (March 2008)
Sponsored by: Peregrine Pharmaceuticals.
Patients must be 18 years or older. Must be off antiretroviral medications or willing to interrupt ARV for 4 weeks prior to and 4 months during study. Must have CD-4 count greater than 300 cells/mm3.
Contact Information: Dr. Jorge E. Rodriguez Newport Beach, CA 92663 Laurie Riney, RN 949-574-2598
Investigational Drug: Principle Investigator, Dr. Mark S. Sulkowski
Looking for Men aged 18 to 50 with hepatitis C to take part in a research study of an investigational drug.
Involves one 36 hour inpatient stay at Johns Hopkins and 14 outpatient visits. Study will last 7 weeks.
You can earn up to $1325.00 for participating.
Please call:
Heather Thomas
Johns Hopkins University
(410) 614 - 6089
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C
This study is currently recruiting patients (May 2007).
Sponsored by: Vertex Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00420784
Purpose
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with peginterferon alfa-2a (Pegasys®), and ribavirin (Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00420784
Central Call Center 877-634-VRTX medicalinfo@vrtx.com
Outside US Call Center 617-444-6777
Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis
The NIH is currently enrolling patients with Hepatitis C associated cryoglobulinemic vasculitis in a research study which takes place at the NIH Clinical Center in Bethesda, MD.
Patients between 18 and 75 years of age with hepatitis C and signs and symptoms of cryoglobulinemic vasculitis may be eligible for this study. They must have failed, or been unable to tolerate, treatment with IFN-a and ribavirin. Candidates will be screened with a history and physical examination, electrocardiogram (ECG), blood and urine tests, 24-hour urine collection and chest X-ray, if clinically indicated.
For more information click here
Latino, Genotype 1: Treatment Naive Only
University Medical Center-Fresno
MUHAMMAD Y. SHEIKH, M.D. 559-459-4042
UC Davis Medical Center
Lorenzo Rossaro, MD 916-734-2911
Transplant Study For People With HIV Infection
A study to evaluate the safety and efficacy of Kidney and liver transplants in a select population of HIV infected individuals is currently in progress at 17+ transplant centers across the country.
Click here for more information
Clinical Trial for Children/Teens with Hepatitis C
One group will be treated with only pegylated interferon, and the second group will be treated with a combination of pegylated interferon and ribavirin
For more information about enrolling in this trial click here
Study: Neurocognitive Effects of HCV, HIV and Drug Use
UCSD HIV Neurobehavioral Research Center
San Diego, CA 92103
The primary objective of this study is to determine the effects of drug use, HCV infection, and HIV infection on neuropsychological performances, including skills of thinking, memory, attention, and concentration.
Inclusion criteria include: 1) Adults between the ages of 18-60, 2) HIV+ and HIV- adults with known or suspected Hepatitis C infection, and 3) no history of interferon treatment.
Evaluation procedures include a one-day full assessment of: interviews & testing, a medical examination, and fluid sampling. For completing this assessment, you will be compensated.
Contact Information:
Teresa Oyos
Study Recruiter
toyos@ucsd.edu
619.543.5016
- Schering-Plough
SCH 50304 Plus Peg-Intron, With and Without Added Ribavirin, in Patients with Chronic Hepatitis C, Genotype 1, who did not respond to peginterferon alfa plus ribavirin.
Click here for more information.
back to top
- Oakland, CA
East Bay Liver Clinic
400-30th St., Ste 200
Oakland, CA 94609
Contact: Grant Young - (510) 208-7777
- Palo Alto, CA
Stanford University Hospital
Stanford Liver Research Clinic
(650) 724-7057
- San Mateo, CA
Clinical Trials and Research
San Mateo Medical Center
222 W. 39th Avenue
San Mateo, CA 94403
Phone: (650) 573-2408
Fax: (650) 571-7802
back to top
- University of California, San Francisco
Clinical Trials
Norah Terrault, MD
(415) 353-2409
- San Francisco VA Medical Center
Sally George, RN, BSN, CRC
San Francisco VA Medical Center
GI Research, 111B
4150 Clement Street
San Francisco, CA 94121
Phone: (415) 221-4810 x3716
Fax: (415) 750-2105
E-mail: Sally.George2@va.gov
- California Pacific Medical Center
Allison Gilchrist, RN, MPH
Work #:(415)600-1768
Email: GilchrA@sutterhealth.org
Anna von Bakonyi, LVN, CCRC
Work #: 415 600-1107
Email: vonbaka@sutterhealth.org
Hepatology Research
Department of Transplantation
California Pacific Medical Center
2324 Sacramento Street
San Francisco, CA 94115
Fax #: (415)600-1108
- San Francisco General
Claudia Ayala (415) 206-3725
back to top
- Dr. John J. Jolley
Contact: Lynn Jolley
Monday, Tuesday, & Wednesday
(415) 257-3030
back to top
- Dr. Gish / Leslie Davison (916) 443-0534
- Dr. Pimstone, UCD Medical Ctr (916) 734-1557
- University of California, Davis Medical Center
Dr. Lorenzo Rossaro (916) 734-8696
back to top
- UC Irvine Medical Center
Dr. John Hoefs, Barbara Walker, RN
(714) 456-7821
back to top
- VA Medical Center Long Beach
Dr. Timothy Morgan, Aliya Asghar, CRC
(562) 826-5212
back to top
- USC Hepatitis Research Clinic
Dr. Karen Lindsay, Susan Milstein, RN
(323) 442-5550
- Cedars-Sinai Comprehensive Transplant Center
Dr. Fred Poordad, Principal Investigator
8631 W. Third St., Suite #430
E Los Angeles, CA 90048
Office: (310) 423-2743 or (310) 423-9545
Fax: (310) 423-0584
back to top
- Jorge E. Rodriguez, MD Principal Investigator
496 Old Newport Blvd., Suite 4
Newport Beach, CA 92663
Office: 949-646-1111
Research: 949-574-2598
Fax: 949-646-6972
back to top
- Santa Barbara/Ventura Counties
Dr. Kip Lyche
(805) 641-6525
(415) 353-0800
back to top
- Scripps Clinic
Helen Broussard (858) 652-5419
- UCSD Medical Center
Petrea (619) 543-3599
- San Diego Medical Associates Research Group
Dr. Michael Bennett
(858) 277-5678
back to top |
